---
title: "\"Performance\" DINGYI GP INV reported a mid-term loss of 485 million yuan, turning from profit to loss"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/267971669.md"
description: "DINGYI GP INV announced its interim results for the six months ending in September, with revenue of 252 million yuan, an increase of 44.6% year-on-year. It recorded a loss of 485 million yuan, compared to a net profit of 27.29 million yuan in the same period last year, turning from profit to loss; the loss per share was 57.05 cents. No dividend was declared"
datetime: "2025-11-30T11:26:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267971669.md)
  - [en](https://longbridge.com/en/news/267971669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267971669.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/267971669.md) | [繁體中文](https://longbridge.com/zh-HK/news/267971669.md)


# "Performance" DINGYI GP INV reported a mid-term loss of 485 million yuan, turning from profit to loss

DINGYI GP INV (00508.HK) announced its interim results for the six months ending in September, with revenue of HKD 252 million, an increase of 44.6% year-on-year. It recorded a loss of HKD 485 million, compared to a net profit of HKD 27.29 million in the same period last year, turning from profit to loss; loss per share was HKD 0.5705. No dividend was declared

### 相关股票

- [DINGYI GP INV (00508.HK)](https://longbridge.com/zh-CN/quote/00508.HK.md)

## 相关资讯与研究

- [Dingyi Group Investment Acquires Zambian Gold Mining License](https://longbridge.com/zh-CN/news/274169325.md)
- [A Look At Fosun International (SEHK:656) Valuation After Recent Mixed Share Price Performance](https://longbridge.com/zh-CN/news/281035263.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [Hong Kong’s Exco approves plans for elevated mass transit system in Kai Tak](https://longbridge.com/zh-CN/news/281144460.md)
- [CSC Financial Sticks to Their Buy Rating for Longfor Group Holdings (LNGPF)](https://longbridge.com/zh-CN/news/280898279.md)